17 Aug Hyoscine Butylbromide – Risk of adverse effects in patients with underlying cardiac disease
Posted at 13:02h
in
lngelheim Pharmaceuticals (Pty) Ltd and Sanofi-Aventis South Africa (Pty) Ltd in collaboration with SAHPRA wish to inform you of the following safety information update regarding the use of hyoscine butylbromide injection as contained in BUSCOPAN 20 mg/1 ml ampoules and BUSCOPAN COMPOSITUM 20 mg/2,5 g injection.
2019 Apr
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
03/04/2019
File Type:
pdf
Category:
Communication To Health Care Professionals